Public Release: 

New therapeutic target for most common solid cancer in childhood?

JCI Journals

A team of researchers, led by Patrick Mehlen, at Université de Lyon, France, has identified the protein NT-3 and the cell-surface molecule to which it binds (TrkC) as potential therapeutic targets for the treatment of neuroblastoma -- the most frequent solid tumor in young children-- by studying human neuroblastoma cells in vitro and after xenotransplantation into mice and chicks.

In the study, NT-3 was found to be expressed at increased levels in aggressive human neuroblastomas and to block the ability of TrkC to induce tumor cell death by a process known as apoptosis. In vitro analysis of human neuroblastoma cell lines indicated that both decreasing NT-3 expression and culturing in the presence of an antibody that blocked NT-3 binding to TrkC triggered the cells to undergo apoptosis. More importantly, blocking the NT-3/TrkC interaction inhibited tumor growth and metastasis in both a chick and a mouse xenograft model of neuroblastoma. The authors therefore suggest that disrupting the NT-3/TrkC interaction might provide a new approach to treating neuroblastoma, a form of cancer for which treatment options are currently limited.

###

TITLE: Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis

AUTHOR CONTACT:

Patrick Mehlen
CNRS UMR5238, Université de Lyon, Lyon, France.
Phone: 33.4.78.78.28.70; Fax: 33.4.78.78.28.87; E-mail:
mehlen@lyon.fnclcc.fr

View this article at: http://www.jci.org/articles/view/41013?key=7f26b0d679e4415a781a

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.